|
| Symptom organ class | Patients, (%) | Antibiotics | Frequency of ADRs, (%) |
|
| Skin and subcutaneous tissue disorders | 576 (45.1) | Quinolone
Penicillin
3rd cephalosporin | 98 (17.0)
88 (15.3)
86 (14.9) |
|
| Gastrointestinal disorders | 416 (32.6) | 3rd cephalosporin
Quinolone
Penicillin | 79 (19.0)
66 (15.9)
61 (14.7) |
|
| Allergic disorders | 125 (9.8) | Glycopeptide
Penicillin
3rd cephalosporin | 24 (19.2)
22 (17.6)
18 (14.4) |
|
| Nervous system disorders | 91 (7.1) | Quinolone
3rd cephalosporin
2nd cephalosporin | 16 (17.6)
14 (15.4)
12 (13.2) |
|
| Blood and lymphatic system disorders | 68 (5.3) | Penicillin
Glycopeptide
3rd cephalosporin | 20 (29.4)
14 (20.6)
8 (11.8) |
|
| Cardiac disorders | 43 (3.4) | Quinolone
3rd cephalosporin
2nd cephalosporin | 8 (18.6)
7 (16.3)
7 (16.3) |
|
| General disorders and administration site conditions | 31 (2.4) | Quinolone
Antiviral agent | 11 (61.1)
2 (11.1) |
|
| Renal and urinary disorders | 24 (1.9) | Glycopeptide
Penicillin
Antifungal agent | 5 (20.8)
5 (20.8)
3 (12.5) |
|
| Respiratory, thoracic, and mediastinal disorders | 23 (1.8) | 3rd cephalosporin
Antifungal agent
Penicillin | 6 (26.1)
5 (21.7)
4 (17.4) |
|
| Hepatobiliary disorders | 23 (1.8) | Anti-TB medication
Penicillin
Carbapenem | 6 (26.1)
3 (13.0)
3 (13.0) |
|
| Eye disorder | 5 (0.4) | Anti-TB medication
Penicillin | 4 (80.0)
1 (20.0) |
|
| Psychiatric disorders | 4 (0.3) | 2nd cephalosporin
Carbapenem
Quinolone | 2 (50.0)
1 (25.0)
1 (25.0) |
|
| Musculoskeletal and connective tissue disorders | 2 (0.2) | Penicillin
Antifungal agent | 1 (50.0)
1 (50.0) |
|
